Embed Size (px)
Citation preview
www.selexis.com
Quick Facts
CORPORATE OVERVIEW1Q 2019
Innovation Leader Selexis SA is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines.
Our global partners are utilizing Selexis technologies to advance more than 100 drug products in clinical development and the manufacture of four commercial products. As part of a comprehensive drug development process, the Company’s technologies shorten development timelines and reduce manufacturing risks.
In June 2017, Selexis became part of the JSR Life Sciences group. JSR’s CDMO service offering leverages the full capabilities of Selexis’ proprietary SUREtechnology Platform™ to offer an end-to-end solution to industry.
Delivering Results In less than 15 years, the Selexis approach to cell line development and protein expression has already generated one of the most impressive portfolios of clinical and commercial cell lines producing a broad range of biotherapeutics from biosimilars to difficult-to-express proteins.1–5
1. SUREtechnology Platform™ Partner pipeline as of May 30, 20182. “Cell Line Development Market Size, Regional Analysis, Competitive Market Share & Forecast, 2023,” Global Markets Insights3. “Cell Line Development Market Analysis and Segment Forecasts 20 20202,” Grandview Research4. Internal research5. Data from third-party disclosures6. SUREtechnology pipeline as of January 16, 20197. Data from client disclosures and internal research
Founded 2001Employees 40+Headquarters Geneva, SwitzerlandStrong Patent Portfolio 154 grantedCell Banks Generated +1800Selexis is the top cell line development firm for number of technology advancements.1–3
Recent Milestones• Joint SAB formation with
KBI Biopharma, Inc.• Expansion of EU laboratories,
R&D unit, BD team• Integration of Berkeley Lights’
Beacon® optofluidic platform to shorten time required to identify and select optimal cell line manufacturing clones
• Named one of “Best Companies to Work for 2018” in Switzerland
Headquarters Selexis SA Chemin des Aulx, 14 1228 Plan les Ouates SWITZERLAND T +41 (0)22 308 93 60 Media Inquiries Mike Beyer Sam Brown, Inc. +1 312 961 2502 [email protected]
REV01FEB2019
PRECLINICAL IND FILING PHASE I PHASE II PHASE III MARKET
AUTOIMMUNE/INFLAMMATORY DISEASES
BLOOD DISORDERS
CANCER
METABOLIC/INFLAMMATORY DISORDERS
DERMATOLOGY/EYE DISORDERS
UNDISCLOSED
20
2
29
1
1
3
3
1
8
1
2
3
18
1
1
10
1
1
3
1
1
2
2
111 DRUG CANDIDATES6,7
4 MARKETED PRODUCTS
www.selexis.com
Corporate Overview1Q 2019
Leadership Team
Licensing Opportunities
Igor Fisch, PhD Chief Executive Officer
Marco Bocci, PhD, DPharm Vice President, European Licensing and Business Development
Regine Brokamp Chief Operating Officer
Pierre-Alain Girod, PhD Chief Scientific Officer
Alberto Gorotti Chief Financial Officer
Yemi Onakunle, PhD, MBA Vice President, US Licensing and Business Development
Selexis has breakthrough cell line development technologies that fundamentally impact and improve drug discovery, development and biopharmaceutical manufacturing.
To discuss business development opportunities, please contact our technology licensing and business development liaison: Déborah Ley, PhD [email protected]
Redefining Best-in-Class Cell Line Development TechnologySelexis’ innovation and expertise have driven the development and ongoing optimization of the most robust and flexible cell line-based protein expression platform in the industry — the SUREtechnology Platform™.
Genome andTranscriptome
Advanced GeneTransfection
Technology andProcedures
ProprietaryCHO-K1Cell Line
Media andFeed Strategies
SURE CHO-MplusLibraries™SUREscan®
SUREsignature™
SUREfeed Strategy™Off-The-Shelf MediaOff-The-Shelf Feed
Selexis SGE®
(Selexis Genetic Elements)SUREtech Vectors™SUREfection Procedures™SUREvariant Screening™
Selexis SURECHO-M Cell Line™(CHO-K1)
Our PromiseHighest yield and stable research cell banks
De-risk regulatory issues while maintaining speed, high productivity and stability
Rescue programs lost due to poor expression
Decrease attrition rates in biologics (lead generation)
Unique documentation fully traceable research cell banks
Continually provide breakthrough technologies
to fundamentally improve the discovery, development and
manufacturing of biologic therapies and vaccines.
Our Mission
REV01FEB2019
Innovation, safety and new therapies impacting
patients’ quality of life
Our Values
Innovative technologies for the rapid development and engineering of clonal
mammalian research cell banks (RCBs)
Full research cell bank documentation with genome characterization, traceability
and “clonality” reports
Our Focus
